NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free RLMD Stock Alerts $3.87 -0.13 (-3.25%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$3.70▼$4.0650-Day Range$3.87▼$6.8052-Week Range$2.36▼$7.22Volume178,113 shsAverage Volume119,258 shsMarket Capitalization$116.76 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Relmada Therapeutics alerts: Email Address Relmada Therapeutics MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside546.0% Upside$25.00 Price TargetShort InterestBearish5.60% of Shares Sold ShortDividend StrengthN/ASustainability-1.45Upright™ Environmental ScoreNews Sentiment0.00Based on 3 Articles This WeekInsider TradingAcquiring Shares$350,305 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.53) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.70 out of 5 starsMedical Sector412th out of 910 stocksPharmaceutical Preparations Industry183rd out of 422 stocks 2.0 Analyst's Opinion Amount of Analyst CoverageRelmada Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.60% of the outstanding shares of Relmada Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Relmada Therapeutics has recently decreased by 3.43%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRelmada Therapeutics has received a 66.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for mood disorders" product. See details.Environmental SustainabilityThe Environmental Impact score for Relmada Therapeutics is -1.45. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Relmada Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $350,305.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.50% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Relmada Therapeutics are expected to grow in the coming year, from ($3.53) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Relmada Therapeutics Stock (NASDAQ:RLMD)Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Read More RLMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLMD Stock News HeadlinesApril 23, 2024 | americanbankingnews.comRelmada Therapeutics (NASDAQ:RLMD) Stock Price Down 3.3%April 16, 2024 | finance.yahoo.comRELMADA THERAPEUT.DL-,001 (4E2.F)April 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 21, 2024 | seekingalpha.comRelmada Therapeutics: Run Up Into Results May Resume Following This DropMarch 21, 2024 | markets.businessinsider.comOptimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial StabilityMarch 20, 2024 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finanznachrichten.deRelmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comQ4 2023 Relmada Therapeutics Inc Earnings CallApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 19, 2024 | investorplace.comRLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023March 19, 2024 | benzinga.comRecap: Relmada Therapeutics Q4 EarningsMarch 19, 2024 | finance.yahoo.comRelmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial ResultsMarch 19, 2024 | prnewswire.comRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 19, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 19, 2024March 18, 2024 | msn.comRelmada Therapeutics FY 2023 Earnings PreviewMarch 16, 2024 | finance.yahoo.comRLMD Apr 2024 2.500 putMarch 5, 2024 | prnewswire.comRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceFebruary 13, 2024 | investing.comRelmada Therapeutics Inc (RLMD)February 5, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Immunocore Holdings (IMCR), Thermo Fisher (TMO)February 4, 2024 | thestreet.comRelmada Therapeutics Inc.February 2, 2024 | msn.comRelmada Therapeutics And 2 Other Penny Stocks Insiders Are BuyingFebruary 1, 2024 | marketwatch.comRelmada Therapeutics Shares Hit 52-Week High After Execs Buy SharesFebruary 1, 2024 | finance.yahoo.comRelmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 SharesJanuary 30, 2024 | benzinga.comRelmada Therapeutics Stock (NASDAQ:RLMD) Dividends: History, Yield and DatesJanuary 23, 2024 | morningstar.comRelmada Therapeutics Inc RLMDJanuary 23, 2024 | finance.yahoo.comRelmada Therapeutics, Inc.'s (NASDAQ:RLMD) market cap touched US$109m last week, benefiting both individual investors who own 39% as well as institutionsJanuary 4, 2024 | realmoney.thestreet.comMizuho sees weakness in Relmada Therapeutics shares as buying opportunitySee More Headlines Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/22/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RLMD CUSIPN/A CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees20Year Founded2004Price Target and Rating Average Stock Price Target$25.00 High Stock Price Target$25.00 Low Stock Price Target$25.00 Potential Upside/Downside+546.0%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($3.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.44% Return on Assets-85.11% Debt Debt-to-Equity RatioN/A Current Ratio8.00 Quick Ratio8.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book1.36Miscellaneous Outstanding Shares30,170,000Free Float26,101,000Market Cap$116.76 million OptionableOptionable Beta0.19 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Sergio Traversa M.B.A. (Age 64)Pharm.D., CEO & Director Comp: $1.79MMr. Maged S. Shenouda M.B.A. (Age 60)R.Ph., Chief Financial Officer Comp: $1.01MMr. Charles S. Ence CPA (Age 59)M.B.A., Chief Accounting & Compliance Officer Comp: $995.03kDr. Paolo Manfredi M.D. (Age 62)Ph.D., Chief Scientific Officer Ms. Gina DiGuglielmoVP & Head of Clinical OperationsDr. Marco Pappagallo M.D. (Age 65)Chief Clinical Officer Mr. John HixonHead of CommercialDr. Andrew CutlerSenior Clinical Development AdvisorDr. Richard M. Mangano (Age 74)Consultant More ExecutivesKey CompetitorsGlycoMimeticsNASDAQ:GLYCAmylyx PharmaceuticalsNASDAQ:AMLXRezoluteNASDAQ:RZLTSagimet BiosciencesNASDAQ:SGMTI-MabNASDAQ:IMABView All CompetitorsInsiders & InstitutionsParsons Capital Management Inc. RIBought 23,679 shares on 4/22/2024Ownership: 3.227%Opaleye Management Inc.Bought 847,000 shares on 2/15/2024Ownership: 2.914%Vestal Point Capital LPBought 115,000 shares on 2/14/2024Ownership: 0.382%AdvisorShares Investments LLCSold 38,242 shares on 2/14/2024Ownership: 0.248%ADAR1 Capital Management LLCBought 58,601 shares on 2/14/2024Ownership: 0.195%View All Insider TransactionsView All Institutional Transactions RLMD Stock Analysis - Frequently Asked Questions What is Relmada Therapeutics' stock price target for 2024? 0 Wall Street research analysts have issued 1 year target prices for Relmada Therapeutics' stock. Their RLMD share price targets range from $25.00 to $25.00. On average, they expect the company's share price to reach $25.00 in the next year. This suggests a possible upside of 546.0% from the stock's current price. View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts. How have RLMD shares performed in 2024? Relmada Therapeutics' stock was trading at $4.14 at the start of the year. Since then, RLMD shares have decreased by 6.5% and is now trading at $3.87. View the best growth stocks for 2024 here. When is Relmada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RLMD earnings forecast. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) issued its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.88) by $0.04. What ETF holds Relmada Therapeutics' stock? AdvisorShares Psychedelics ETF holds 72,123 shares of RLMD stock, representing 4.53% of its portfolio. Who are Relmada Therapeutics' major shareholders? Relmada Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Parsons Capital Management Inc. RI (3.23%). Insiders that own company stock include Cedric O'gorman, Charles J Casamento, Chuck Ence, Maged Shenouda, Paul Edward Kelly and Sergio Traversa. View institutional ownership trends. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RLMD) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
